im not suggesting that BAL is not a good business and would not add synergies due to the similarities as outlined earlier, but i believe bal is still overpriced and a takeover would require a premium to sp, so i dont think bkl should consider it unless the sp dropped below 8-10 despite a decent market outlook.
m&a is not without its pitfalls even when synergy potential and market overlap is high as seen recently with voc.
i think bkl mx team has enough on its plate concentrating on success in new markets rather than trying to juggle m&a as well
- Forums
- ASX - By Stock
- BKL
- the new under the oldrse
the new under the oldrse, page-84
-
-
- There are more pages in this discussion • 86 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BKL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online